You are here: Research > Research We Are Funding > Research we are funding

Scientist Image

Research we are funding

We are currently funding a range of exciting projects and programmes, all of which aim to enhance our understanding of retinitis pigmentosa (RP) and related conditions, and inform the development of treatments for the estimated two million people affected worldwide.

Identification and functional characterisation of the missing ABCA4 variants in Stargardts Disease
July 2017 – June 2020
ABCA4 mutations affect the majority of people with recessive Stargardt disease and about 30% of those with con-rod dystrophy. This project aims to develop a cost-effective sequencing method for the entire ABCA4 gene, sequence 1,000 Stargardt’s cases worldwide and finalise a process for testing the effects of mutations. Ultimately the diagnosis of people with an ABCA4 mutation will be improved, and the identification of those suitable for participation in future clinical trials made easier.

Modelling effects of TIMP-3 mutations in RPE – insights into Sorsby disease and night blindness in retinal dystrophies
November 2017 – October 2020
This project aims to explore how changes in a protein called TIMP-3 damage the retinal pigment epithelium (RPE), leading to Sorsby Fundus dystrophy. The team will also look at whether gene editing technology might be a viable treatment for the condition.

Non-viral gene therapy using S/MAR vectors for Usher Syndrome
January 2018 – December 2020
This project explores an alternative to traditional gene therapy, which may have implications for a wide range of inherited retinal dystrophies, not just Usher syndrome. S/MAR vectors have the capacity to hold much larger genes, and they have no viral components. The team will explore whether this new approach represents a safe and effective future treatment option.

RPFB centre for the development of gene therapy for inherited retinal dystrophies – The Gene Team
August 2011 – February 2018
As a result of major advances over the last two decades, gene therapy for retinal disorders is now a realistic prospect. Professor Robin Ali’s team at the UCL Institute of Ophthalmology has been establishing the viability of this potential treatment. Their aim is to build a programme of clinical trials for various forms of retinal dystrophy, focusing in the first instance on those disorders for which there are the best proof-of-concept studies.
Update
A state of the art adaptive optics (AO) imaging system at Moorfields Eye Hospital is being used to image the retina with an unparalleled degree of clarity and precision. The team continues to develop its pipeline of therapies and five ongoing ethically approved studies aim to clinically categorise patients in preparation for future trials. More than 40 publications have been generated by The Gene Team to date.
Take a look at the latest update from the Gene Team

Pharmacological therapies for Rhodopsin RP
March 2013 – July 2017
Inherited mutations in rhodopsin, the light sensing protein of rods cells, are the single most common case of autosomal dominant RP. Previous research conducted by Professor Mike Cheetham had identified a number of promising drug treatments which can delay photoreceptor degeneration and lead to improvements in photoreceptor function. His current project aims to advance pre-clinical development of these drugs, quantifying their efficacy and suitability for the various rhodopsin mutations present in the UK patient population. Ultimately, this study will facilitate the future translation of these promising pre-clinical findings to the clinic trials stage.
Update
Professor Cheetham’s team has completed the first round of screening of potential drugs and is studying the most common of the UK’s rhodopsin mutations. They have identified the three most beneficial drugs (HSP990, Arimoclomol and TUDCA) for more extensive testing.

The development of human iPSC-derived ex vivo models of retinal degeneration and their analysis in splicing-factor RP.
April 2014 – May 2017
RP causes the degeneration of the retina due to events occurring within specialised and inaccessible retinal cells. A recent innovation allows the creation of stem cells from human skin and the transformation of these into retinal cells for use in the laboratory. Professor Webster’s team will use this technology to investigate cells from patients with certain forms of RP. Their discoveries will inform the development of future treatments for the condition.
Update
The team have undertaken detailed analysis of a number of patient samples to identify the root genetic cause of the mechanisms by which the retinal cells are damaged. They have also investigated samples from carriers of a disease-causing mutation, some of whom show symptoms of RP and some of whom do not, in an attempt to identify why this might be.

Maintaining effective antioxidant capacity in a degenerating retina: a genetic approach to treatments in RP
August 2014 – July 2017
Gene therapy can restore function in many forms of RP, but it may not prevent further degeneration unless treatment begins early. The difficulty in slowing the degeneration of the retina could be because, while many genes can initiate the disease, the resulting abnormal retinal state can drive it forwards. Therefore, identifying the factors driving rather than initiating the degeneration could form the basis for useful future treatments. This project seeks to investigate antioxidant pathways within the retinal mitochondria as a step towards treating the oxidative stress which is a key factor in degeneration.
Update
Professor Ali’s team were able to detect artificially produced changes in oxidative stress within retinal cells, and will apply the same measuring techniques to disease-induced changes. They are using these techniques to test the effects of intervention procedures, mainly small molecule antioxidants, as well as gene therapy approaches.

The RP Genome Project
November 2014 – October 2017
The RP Genome Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs): The University of Leeds, London’s UCL Institute of Ophthalmology, Manchester Royal Eye Hospital and Oxford University Eye Hospital. It was the first project of its kind in terms of the level of collaborative working required for its success. Since then, four further sites have been added to the study, widening the scope for collaboration and the availability of data and resources. The new sites are in Southampton, Bristol, Cardiff and Great Ormond Street Hospital.
Update
The consortium has become a Genetics England Clinical Interpretation Partnership (GECIP) associated with the UK 100,000 Genome Project. This allows the team to ensure that ophthalmic genetics are well positioned among the 100,000 genomes being sampled and one of the consortium investigators has been chosen to lead the GECIP in the field of Ophthalmology. The consortium has had 13 papers published, with nine in proposal. The team has identified new disease-causing genes and mutations, finding the genetic basis for disease in more than 230 cases.
Take a look at the latest update from the RP Genome Project

Supporting the triage of LCA patients for AIPL1-targeted gene therapy through functional validation of uncharacterised and novel AIPL1 variants
August 2015 – October 2017
Leber congenital amaurosis (LCA) has many similarities to RP and is characterised by severe loss of vision early in life. This project aims to identify which variations of a certain gene, AIPL1, are disease causing mutations.
Update
The team has been able to establish conclusive evidence confirming the disease-causing status of AIPL1 variations detected in patients with Leber congenital amaurosis (LCA) recruited at Moorfields Eye Hospital. These findings are critical for supporting the accurate diagnosis and effective triage of LCA patients with these mutations.

DNA Damage as a Driver of Photoreceptor Loss in X-linked Retinitis Pigmentosa
November 2016 – October 2018
Mutation of the RP2 gene causes retinitis pigmentosa but the mechanism by which this happens is still not fully understood. Current data suggests that a reduced ability to deal with oxidative stress and DNA damage may be the issue, and this project aims to explore whether this is the underlying cause. It will also test whether drugs which target DNA repair pathways and/or antioxidant therapies represent a suitable treatment option.

Aberrant RNA processing in Retinal Dystrophies: understanding mechanisms and developing therapies
January 2017 – December 2019
The retina needs a large number of genes to function, and these genes are required to make a number of different products through a process called ‘splicing’. Gene mutations that might be tolerated elsewhere in the body can cause disease in the retina when this splicing process goes wrong. This project aims to build on previous research to better understand why this happens, and test potential treatments using stem cell technology.

We are only able to fund exciting research like this thanks to our wonderful supporters. Please consider making a donation today to help our work continue or find out about other ways you can help.


donate to us with CAF
 

RP Online

RP on Facebook The RP blog Follow RPdch on Twitter